Phil Taylor at pharmaphorum | Contact Details

Media Database

>

Phil Taylor

Contact this person

Email address

p*****@*******.comGet email address

Influence score

32

Phone

(XXX) XXX-XXXX Get mobile number

Location

United Kingdom

Languages

English

Covering topics

General Assignment News
Health & Medicine

View more media outlets and journalists by signing up to Prowly

View latest data and reach out all from one place

Sign up for free

Recent Articles

pharmaphorum.com

ODAC unpicks AZ's Imfinzi trial in perioperative NSCLC - pharmaphorum

FDA’s ODAC doesn’t vote on AstraZeneca’s perioperative Imfinzi regimen in NSCLC but has deep reservations about the design of the phase 3 trial supporting it

9 months ago

pharmaphorum.com

Study finds wearables deliver key insights in heart disease - pharm...

Consumer wearables have shown a benefit when used to monitor treatment responses in patients with atrial fibrillation and heart failure.

9 months ago

pharmaphorum.com

IT outage raises resilience, security concerns in healthcare - phar...

As healthcare systems try to recover from major outage event, attention turns to potential fraud and resiliency concerns

9 months ago

pharmaphorum.com

Re-elected von der Leyen pledges EU measures for biotech - pharmaph...

Ursula von der Leyen highlights biotech and AI as key sectors in speech as she is re-elected as President of the European Commission

9 months ago

pharmaphorum.com

Call goes out for simpler clinical trial regulation in UK - pharmap...

Framework governing early-stage clinical trials in the UK is stifling research and needs to be simplified, says BJCP paper

9 months ago

pharmaphorum.com

Novo leads $100m financing for Alzheimer's player Asceneuron - phar...

Novo Holdings leads $100m financing for Swiss biotech Asceneuron, which is developing an oral tau therapy for Alzheimer’s disease

9 months ago

pharmaphorum.com

UK’s Destiny Pharma hops on the AIM delisting train - pharmaphorum

Destiny Pharma has joined a growing list of UK biotech companies seeking to delist from the AIM exchange and return to private ownership

9 months ago

pharmaphorum.com

Investors take issue with Taisho Pharma’s buyout price - pharmaphorum

Two investment funds have decided to contest Taisho Pharma’s recently announced management buyout plan in court

9 months ago

pharmaphorum.com

Flagship closes $3.6bn biotech fund, with a focus on AI - pharmaphorum

Flagship Pioneering raises $3.6bn to fund around 25 startups in human health, sustainability and AI, with $1bn set aside for strategic partnerships

9 months ago

pharmaphorum.com

Study finds GLP-1 drugs may cut obesity-related cancers - pharmaphorum

GLP-1 agonists like Novo Nordisk’s Ozempic reduce the risk of 10 of 13 cancers associated with obesity in an observational study.

9 months ago

pharmaphorum.com

Private equity firms 'eyeing $20bn for Sanofi consumer unit' - phar...

Private equity firms Bain Capital and Cinven are reported to be considering a bid for Sanofi’s consumer health business

9 months ago

Phil Taylor

News Editor at pharmaphorum

View more media outlets and journalists by signing up to Prowly

Recent Articles